JT
NTLA icon

Jupiter Topco’s Intellia Therapeutics NTLA Stock Holding History

Jupiter Topco’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$812K Buy
+47,957
New +$671K ﹤0.01% 1876

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco's NTLA Position: Q2 2026 in Review

Jupiter Topco opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 47,957 shares worth $812K. The stake represents ﹤0.01% of the portfolio and ranks #1876 among its holdings.

306 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Jupiter Topco held 47,957 shares of Intellia Therapeutics worth $812K as of Q2 2026.
  • Intellia Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #1876 holding.
  • 306 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.